<DOC>
	<DOCNO>NCT00652132</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Chemoprotective drug , sodium thiosulfate , may protect normal cell side effect chemotherapy . It yet know whether give sodium thiosulfate effective reduce hearing damage cause cisplatin treat young patient liver cancer . PURPOSE : This randomized phase III trial study well sodium thiosulfate work decrease hearing loss cause cisplatin treating young patient stage I , stage II , stage III childhood liver cancer .</brief_summary>
	<brief_title>Cisplatin With Without Sodium Thiosulfate Treating Young Patients With Stage I , Stage II , Stage III Childhood Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess efficacy sodium thiosulfate ( STS ) reduce hear impairment cause cisplatin chemotherapy . Secondary - To carefully monitor potential impact STS response cisplatin survival . - To assess short- long-term tolerability combination STS cisplatin - To prospectively evaluate validate biological , radiological pathological feature standard-risk hepatoblastoma future risk adapt management - To investigate effect STS formation cisplatin-DNA adduct . - To prospectively collect patient DNA specifically analysis possible genetic factor may contribute development treatment-related ototoxicity nephrotoxicity OUTLINE : This multicenter study . Patients stratify accord country , median age ( &lt; 15 month vs ≥ 15 month ) , PRETEXT tumor classification ( I vs II v III ) . Patients randomize 1 2 treatment arm . - Arm I ( Neoadjuvant adjuvant cisplatin ) : Patients receive cisplatin IV 6 hour day 1 . Treatment repeat every 2 week 4 course . Patients progressive disease course 4 take study . Patients without evidence disease progression proceed surgery . Beginning within 3 week surgery , patient receive cisplatin IV 6 hour day 1 . Treatment repeat every 2 week 2 course absence disease progression unacceptable toxicity . - Arm II ( Neoadjuvant adjuvant cisplatin sodium thiosulphate ) : Patients receive cisplatin IV 6 hour sodium thiosulphate IV 15 minute ( begin 6 hour completion cisplatin ) day 1 . Treatment repeat every 2 week 4 course . Patients progressive disease course 4 take study . Patients without evidence disease progression proceed surgery . Beginning within 3 week surgery , patient receive cisplatin IV 6 hour sodium thiosulphate IV 15 minute ( neoadjuvant therapy ) day 1 . Treatment repeat every 2 week 2 course absence disease progression unacceptable toxicity . Patients undergo blood collection tumor biopsy periodically biological pharmacological study consist biomarker analysis , gene expression profiling , IHC , proteomic analysis , gene rearrangement analysis . Patients undergo auditory evaluation baseline , completion study treatment age least 3.5 year measure ototoxicity hearing impairment . After completion study treatment , patient follow periodically least 5 year .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Hepatoblastoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Sodium thiosulfate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm standardrisk hepatoblastoma , meet follow criterion : PRETEXT I , II III disease Serum alphafetoprotein ( AFP ) &gt; 100 μg/L No additional PRETEXT criterion Newly diagnose disease Must start study treatment within 15 day confirm biopsy No highrisk hepatoblastoma meeting follow criterion : Tumor involve 4 hepatic section ( PRETEXT IV ) Any follow additional PRETEXT criterion : Extrahepatic abdominal disease ( E1 , E1a , E2 , E2a ) Intraperitoneal hemorrhage tumor rupture ( H1 ) Distant metastases , site ( M1 ) Lymph node metastasis ( N1 , N2 ) Involvement main portal vein ( P2 , P2a ) Involvement three hepatic vein and/or inferior vena cava ( V3 , V3a ) No recurrent disease No hepatocellular carcinoma Must provide adequate material central review ( radiology , pathology , audiology ) feasible , tissue storage program Must available audiology center test child minimum require quality standard PATIENT CHARACTERISTICS : Glomerular filtration rate ≥ 75 % low limit normal age ( ≥ 60 mL/min patient ≥ 2 year old ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able follow study protocol No prior hypersensitivity sodium thiosulfate PRIOR CONCURRENT THERAPY : No prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>ototoxicity</keyword>
	<keyword>childhood hepatoblastoma</keyword>
	<keyword>stage I childhood liver cancer</keyword>
	<keyword>stage II childhood liver cancer</keyword>
	<keyword>stage III childhood liver cancer</keyword>
</DOC>